Please use this identifier to cite or link to this item:
Title: Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.
Austin Authors: Tang, Monica;Price, Timothy Jay;Shapiro, Jeremy;Gibbs, Peter;Haller, Daniel G;Arnold, Dirk;Peeters, Marc;Segelov, Eva;Roy, Amitesh;Tebbutt, Niall C ;Pavlakis, Nick;Karapetis, Chris;Burge, Matthew
Affiliation: NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia
Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia
Medical Oncology, Cabrini Hospital, Malvern, Australia
Medical Oncology, Monash University, Melbourne, Australia
Systems Biology and Personalised Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
Medical Oncology, Flinders University, Bedford Park, Australia
Abramson Cancer Center at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Medical Oncology, Asklepios Tumorzentrum Hamburg, Hamburg, Germany
Medical Oncology, University Hospital Antwerp, Oncology, Edegem, Belgium
Medical Oncology, Monash Medical Centre, Clayton, Australia
Medical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, Australia
Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Medical Oncology, Royal North Shore Hospital, St Leonards, Australia
Medical Oncology, Flinders Medical Centre, Bedford Park, Australia
Medical Oncology, University of Queensland, Brisbane, Australia
Issue Date: Apr-2018 2018-03-01
Publication information: Expert review of anticancer therapy 2018; 18(4): 339-349
Abstract: Oxaliplatin-based adjuvant chemotherapy has been the standard of care for resected early colon cancer for over a decade. Recent results from the IDEA meta-analysis attempt to address the question of whether 3 or 6¬†months of adjuvant chemotherapy is preferable in Stage III colon cancer. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of adjuvant therapy for resected early colon cancers. This article reviews the current evidence for adjuvant treatment of Stage II and III colon cancer, as well as up-to-date data regarding optimal duration of therapy. This article reviews the evidence for lifestyle modifications in the management of early colorectal cancer and other future directions for research in early colon cancer. Expert commentary: In recent years, there have been no advances in the development of novel agents for adjuvant therapy in colorectal cancer. Although the IDEA meta-analysis was negative for its primary non-inferiority endpoint, the detailed results provide valuable information that allows personalisation of treatment regimen and duration.
DOI: 10.1080/14737140.2018.1444481
ORCID: 0000-0003-0075-2176
PubMed URL: 29478352
Type: Journal Article
Subjects: Colon cancer
IDEA collaboration
adjuvant treatment
duration of chemotherapy
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.